Acute Heart Failure Syndromes: Current State and Framework for Future Research
暂无分享,去创建一个
Luigi Tavazzi | Gerasimos Filippatos | Liviu Klein | Faiez Zannad | I. Piña | G. Filippatos | L. Tavazzi | M. Gheorghiade | F. Zannad | B. Massie | M. Konstam | S. Collins | G. Sopko | L. Klein | Barry M Massie | Ileana L Piña | Marvin A Konstam | George Sopko | S. Targum | Mihai Gheorghiade | Sean P Collins | Edmond Roland | Shari Targum | E. Roland
[1] G. Fonarow,et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. , 1997, Circulation.
[2] J. Ghali,et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .
[3] W. Peacock,et al. 368 Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE® Registry , 2004 .
[4] Peter C. Austin,et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.
[5] Christopher M O'Connor,et al. Risk stratification after hospitalization for decompensated heart failure. , 2004, Journal of cardiac failure.
[6] N. Freemantle,et al. The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.
[7] J. Papp,et al. STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL , 2002 .
[8] K. Adams,et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.
[9] C. O'connor,et al. The impact of arrhythmias in acute heart failure. , 2004, Journal of cardiac failure.
[10] A. Katz. A new inotropic drug: its promise and a caution. , 1978, The New England journal of medicine.
[11] J. Cohn,et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. , 1985, Annals of internal medicine.
[12] C. O'connor,et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. , 2003, The American journal of cardiology.
[13] James B. Young. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .
[14] Y. Moshkovitz,et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.
[15] N. Freemantle,et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .
[16] K. Adams,et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.
[17] R. Califf,et al. Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study , 2005, Circulation.
[18] Christopher M O'Connor,et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.
[19] J. Hollander,et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. , 2004, Journal of the American College of Cardiology.
[20] B. Winkelmann. American Heart Association Scientific Sessions , 2004, Expert opinion on investigational drugs.
[21] R. Califf,et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.
[22] G. Fonarow,et al. Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.
[23] K. Dickstein,et al. [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[24] M. Gheorghiade,et al. ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL , 2004 .
[25] P. Sobotka,et al. Effect of acute edema on left ventricular function and coronary vascular resistance in the isolated rat heart. , 1994, The American journal of physiology.
[26] S. Gottlieb,et al. BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy , 2002, Circulation.
[27] K. Aaronson,et al. Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.
[28] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[29] Doron Aronson,et al. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. , 2004, The American journal of medicine.
[30] K. Aaronson,et al. Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials , 2005 .
[31] G. Heusch,et al. Development of Short‐term Myocardial Hibernation Its Limitation by the Severity of Ischemia and Inotropic Stimulation , 1993, Circulation.
[32] Christopher M O'Connor,et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. , 2004, JAMA.
[33] J. Cleland,et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.
[34] K. Adams,et al. Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology: analysis of 33,046 patients in the ADHERE registry , 2003 .
[35] W John Boscardin,et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.
[36] N Freemantle,et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.
[37] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[38] W. Abraham,et al. Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.